Endeavor Power Corporation (“Endeavor Power” or the “Company”) (OTCQB: EDVP) is announcing that it has changed the name of its wholly owned operating subsidiary Parallax Diagnostics, Inc. and moved its corporate headquarters. The Company announced today that it has approved the changing of the name of its wholly owned subsidiary Parallax Diagnostics, Inc. to Endeavor Sciences, Inc. The Company believes the name change was a necessary evolvement as the Company furthers its execution of its business plan in the infectious disease point of care diagnostic space. In addition the Company announces that it has relocated its corporate headquarters from its former location at 84 Winnisimmet Drive Chelsea, MA 02150 to its new headquarters at 2 Canal Park 5 th Floor Cambridge, MA 02141. ABOUT ENDEAVOR POWER CORPORATION. Endeavor Power Corp is a fully reporting Nevada corporation traded on the OTCQB under the symbol “EDVP.QB”. The Company is headquartered in Cambridge, MA. Parallax Diagnostics, Ltd (“Parallax”) is a bio-medical company focused on infectious diseases, which owns a line of proprietary, FDA approved, Point of Care diagnostic tests on a single proprietary platform. Parallax is developing a novel, handheld diagnostic testing system that is simple, rapid and elegant, offering the potential to transform the diagnostic landscape by transitioning critical tests from the centralized lab directly to the hands of the physician or clinicians. Our focus is on tests that detect and/or monitor infectious diseases. The Company’s tests combine innovative technologies that provide accessible, practical and rapid point of care in vitro diagnostics are based on the Company’s Target System, its FDA Approved Platform that centered on the Target System VT1000, an FDA Approved bench top fluorescence immunoassay spectrum analyzer and its innovative flow through Target System test cartridges. For more information: www.endeavorpowercorp.com or visit Endeavor Power Corp. on Facebook, Twitter, and You Tube. FORWARD-LOOKING STATEMENTS This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our reports filed with the SEC. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.